查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844086

按治療類型、給藥途徑、最終用戶和骨折類型分類的骨質疏鬆症和骨折治療市場—2025-2032年全球預測

Anti-Osteoporosis Therapy & Fracture Healing Market by Therapy Type, Route Of Administration, End User, Fracture Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，骨質疏鬆症和骨折治療市場將成長至 293.5 億美元，複合年成長率為 8.78%。

主要市場統計數據
基準年 2024 149.7億美元
預計年份：2025年 162.8億美元
預測年份：2032年 293.5億美元
複合年成長率 (%) 8.78%

簡明框架闡述了影響骨質疏鬆症和骨折治療領域的臨床重點、治療方法進展和醫療服務模式動態。

骨質疏鬆症和骨折治療在老齡化社會的醫療保健策略和全球治療創新議程中佔據核心地位。隨著人口結構變化導致高風險族群不斷擴大，臨床路徑、支付方期望和醫療服務模式也在同步演變。這種互動將影響臨床醫生、醫院系統、支付方和製造商決策的臨床需求和商業性現實結合起來。

目前，低骨量和脆性骨折的治療依賴於藥物、器械干預以及以二級預防為重點的協調護理體系的協同作用。同時，長期治療依從性、給藥途徑偏好以及新型生技藥品的出現正在重塑治療流程。監管核准、安全性資訊和真實世界證據正在以因地區而異的方式影響製劑研發者的信心和配製實踐。

在此背景下，相關人員必須權衡臨床療效與營運可行性，並認知到成功的骨折預防和治療方案需要基層醫療、專科診所、醫院和居家照護服務之間的整合。這項認知為策略性地解讀以下章節奠定了基礎，這些章節將分析產業轉型、貿易政策影響、市場區隔資訊、區域動態、競爭對手活動，並為希望將洞察轉化為行動的領導者提供切實可行的建議。

生技藥品、以病人為中心的給藥方案、精準治療管道以及供應彈性如何重塑治療策略和商業模式

骨質疏鬆症和骨折治療的治療格局和競爭格局正經歷多重加速的同步轉變，這些轉變正在改變臨床和競爭定位。首先，單株抗體療法和合成代謝藥物的成熟正在將治療順序轉向快速降低骨折風險和促進骨骼生長的策略，促使臨床醫生重新審視他們長期以來對單藥抗骨吸收療法的依賴。

其次，以病人為中心的照護模式和注重依從性的醫療器材創新正在提升給藥途徑和給藥便利性的重要性。與每日或每週口服療法相比，劑量精準的注射療法正在改變患者的依從性，這種變化促使支付方和醫療服務提供者重新思考護理路徑和支持服務。第三，精準醫療和數位健康的整合正在實現更精細的風險分層，影像生物標記和綜合骨折聯絡服務有助於提高病例檢出率和及時干預能力。

最後，供應鏈韌性和生物相似藥的競爭正成為商業規劃中的策略變數。製造商正透過多元化產品組合、對已上市藥物進行生命週期管理以及加速整合臨床服務、診斷和患者支持的夥伴關係來適應這些變化。雖然這些變革性轉變增加了商業化的複雜性，但也創造了在臨床效益和營運可擴展性之間取得平衡的差異化路徑。

評估2025年關稅調整對骨質疏鬆症醫療保健供應鏈、採購和治療取得的營運和策略影響。

2025年關稅調整和貿易政策變更的實施，為骨質疏鬆症和骨折治療產品相關相關人員帶來了新的成本和供應方面的考量。對藥品原料和成品徵收關稅可能會增加到岸成本，尤其是對於複雜的生技藥品原料和某些依賴國際採購的專用成分的治療層級。這反過來又會影響醫院系統和專科診所的價格談判、籌資策略和庫存管理決策。

製造商和經銷商正在透過重新評估其全球製造地、加大近岸外包投資以及加快替代原料藥和輔料供應商的資質認證來應對，以確保供應的連續性。同時，支付者和綜合醫療系統正在加強對成本效益的審查，並可能優先考慮供應鏈穩定、成本結構透明的治療方案。這些趨勢既帶來了挑戰，也帶來了機會。雖然關稅會造成短期利潤壓力和採購複雜性，但它們也會促使企業投資於具有韌性的生產、垂直整合以及策略供應商聯盟，從而降低未來貿易中斷的風險。

此外，監管機構和海關部門越來越重視文件記錄和可追溯性，這就要求品質、法規和商業團隊之間加強合作。對於創新者和現有產品所有者而言，積極規劃供應鏈方案並與採購相關人員合作至關重要，這有助於減輕關稅調整帶來的累積營運影響，並確保臨床醫生和患者能夠獲得關鍵治療方法。

分析治療層級、給藥途徑、治療環境和骨折特定需求，以使臨床證據與商業性策略一致，從而提高產品普及率。

解讀市場區隔的細微差別，可以揭示臨床需求、商業機會和營運摩擦的交匯點，而將這些細分市場的特徵轉化為可執行的策略至關重要。治療方法類型涵蓋了從經典的抗骨吸收藥物（例如雙磷酸鹽）到阿崙膦酸鈉、Ibandronate sodium、利塞膦酸鈉和Zoledronic acid等藥物。荷爾蒙補充療法包括聯合治療和以雌激素為重點的治療策略。單株抗體療法包括Denosumab和Denosumab，其商品名分別為Prolia和Xgeva。副甲狀腺素類似物包括阿巴洛帕肽和特立帕肽。選擇性雌激素受體調節（例如Bazedoxifene和Raloxifene）在特定患者群體中繼續佔據一定的市場地位。這些治療方法的差異性取決於療效、安全性、患者合併症和製劑定位等因素，進而推動臨床應用。

在考慮給藥途徑時，注射和口服途徑必須權衡患者的便利性、對順從性的影響以及醫療服務能力。可用於靜脈或皮下注射的注射劑通常需要醫療機構資源或經過培訓的居家照護服務，而門診病人，但面臨依從性方面的挑戰。就最終用戶而言，服務提供場所包括居家醫療機構、醫院和專科診所，每種場所都有其獨特的採購、管理和報銷動態，這些都會影響產品選擇和支援需求。對骨折類型進行細分，可以揭示臨床優先領域——髖部、脊柱和手腕關節骨折——這些領域在患病率、急性護理需求和復健途徑方面的差異反映了治療的緊迫性和二級預防策略。這種綜合細分有助於產生有針對性的臨床證據、客製化患者支援計畫以及製定針對特定管道的商業策略，從而最佳化患者的接受度和治療效果。

美洲、歐洲、中東和非洲以及亞太地區在監管、報銷和供應方面的差異將決定其准入和推廣管道。

區域動態持續影響骨質疏鬆症治療和骨折管理方案的取得、報銷和臨床應用模式。在美洲，整合式醫療服務體系、以支付方主導的配藥流程，以及日益重視與骨折和再入院率等結果掛鉤的價值導向型契約，都在影響著市場需求。這些壓力促使生產者展示產品在實際應用中的有效性，並與醫療系統合作進行上市後實證研究和病患支援計畫。

在歐洲、中東和非洲，監管協調、國家採購框架和不同的報銷環境造就了多種多樣的市場參與策略。各國在價格談判機制和衛生技術評估方法上的差異，使得市場准入計畫和針對特定臨床和經濟終點的本地證據變得至關重要。該地區也為進行深入的臨床合作和區域製造投資提供了機遇，從而提高了供應安全。

亞太地區的市場發展軌跡各不相同，有的高所得都市區正迅速擴大先進生技藥品的可近性，有的新興市場則不斷提升基層醫療能力。部分市場的地方監管趨勢、臨床試驗的活性化以及對診斷基礎設施投資的加大，正在推動創新藥物的快速普及，而成本和物流問題則在其他市場構成重大障礙。在所有地區，最佳實踐的骨折聯絡服務和跨境遠端醫療監測合作正成為提升病患療效和擴大治療覆蓋範圍的關鍵因素。

競爭策略的核心是提供生技藥品創新、生命週期管理、夥伴關係和整合服務，從而塑造產品發展軌跡。

在骨質疏鬆症和骨折治療領域，各公司的策略涵蓋多種途徑，從產品組合多元化和生物創新到生命週期管理和服務整合。一些領先的創新企業正專注於單株抗體和合成代謝劑平台的開發，利用差異化的臨床特徵來確保製劑優勢並獲得專家的認可。這些公司正大力投資長期安全性監測、頭對頭試驗和大規模觀察性研究，以維持臨床醫生的信心並影響指南的發展。

同時，擁有成熟小分子藥物組合的公司正優先考慮成本控制策略、生產最佳化以及能夠提高患者依從性的患者支援服務。隨著各公司致力於為骨折預防和治療提供一站式解決方案，診斷服務提供者、居家照護業者和數位醫療公司之間的合作日益普遍。生物相似藥的參與企業和契約製造生產商正在影響定價動態和供應靈活性，迫使原廠藥企業加快創新步伐，並探索新的商業模式，例如基於療效的定價模式。

從競爭格局來看，智慧財產權管理、監理生命週期規劃和地域性生產多元化是反覆出現的主題。那些擁有強力的臨床證據、穩健的供應鏈和一體化服務產品的公司，更有利於保持競爭力；而那些未能適應不斷變化的支付方要求和患者期望的公司，則面臨在關鍵通路市場佔有率下降的風險。

以實證實踐、供應鏈韌性、以患者為中心的醫療服務以及新型商業模式為重點，採取切實可行的策略舉措，以確保競爭優勢。

產業領導者應採取一系列協調一致的策略行動，使臨床差異化與營運韌性以及支付方的期望一致。首先，應優先產生真實世界證據和比較療效數據，以證明其臨床效用和系統價值，從而增強與支付方的談判能力，並使其能夠納入以指南為導向的診療路徑。其次，應投資於供應鏈多元化和近岸外包，以降低關稅和貿易中斷帶來的風險，同時透過資格確認流程確保品質和合規性。

第三，我們將設計以病人為中心的支持計畫和給藥途徑，結合口服藥物的便利性和注射療法的依從性優勢。第四，我們將與診斷機構和骨折聯絡服務機構進行策略合作，以最佳化病例發現和二級預防流程。第五，我們將探索適應性商業模式，例如骨折治療的風險分擔協議和打包支付，以協調各相關人員的獎勵。

最後，在產品開發和生命週期活動的早期階段就納入監管和衛生技術評估計劃，可以加快產品上市速度，並主動滿足支付方的證據要求。透過協調臨床、營運和商業方面的優先事項，企業領導者可以將新興趨勢轉化為永續的競爭優勢。

一種綜合性的、經過同儕檢驗的研究途徑，結合了第一手資料和第二手資料。

本分析的調查方法整合了多種證據來源、同行檢驗和迭代三角測量，以得​​出可操作的見解。主要研究包括與內分泌科和整形外科臨床專家、醫院藥屋主任、專科診所經理以及支付方和採購代表進行結構化訪談和諮詢討論，從而獲得關於配藥行為、配藥決策和醫療服務限制的第一手觀點。

二次研究包括對監管核准、同行評審的臨床文獻、指南聲明、產品標籤和公開的安全資訊進行系統性回顧，以確認其與近期臨床和監管進展的一致性。此外，還查閱了真實世界資訊來源，例如醫療資源利用報告、臨床註冊研究和已發表的結局研究，以闡明治療結果和上市後經驗。

資料綜合依賴於原始研究結果和二手資料集的交叉驗證，並採用主題編碼來識別反覆出現的機會和風險。情境分析和敏感性測試用於評估供應鏈和貿易政策變化對營運的影響。在整個研究過程中，品質保證通訊協定確保了資料來源的可追溯性和一致性，專家對研究結果草稿進行了審查，以確保其臨床和商業性相關性。

將治療方法創新、服務模式轉型和營運韌性聯繫起來的集體智慧，為在骨折預防和治療方面產生持久影響指明了清晰方向。

總之，骨質疏鬆症和骨折的治療格局正處於曲折點，其驅動力包括治療創新、不斷演變的醫療服務模式以及新的供應鏈和貿易考量。合成代謝類固醇和單株抗體動態的興起正在重塑臨床決策，而用藥依從性和給藥途徑的動態變化則持續影響實際療效。同時，關稅以及支付方日益關注治療結果等因素也正在重塑商業化策略和產業計畫。

積極整合可靠的證據生成、靈活的生產和籌資策略以及以患者為中心的服務模式的利益相關人員，將更有能力應對這一複雜的環境。連結診斷、數位健康和​​護理協調服務的跨部門合作，有望提高病例檢出率並減輕後續骨折負擔。最終，那些將科學差異化、可驗證的價值以及醫療保健系統穩健運作相結合的機構，將在成熟市場和新興市場中獲得持久的機會。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 羅莫索單抗療法的進展正受到嚴格審查，以評估其對高風險骨質疏鬆症患者的心血管安全性。
  • 整合穿戴式感測器和人工智慧演算法，即時監測骨癒合進展
  • 利用基因治療方法標靶成骨細胞活性，促進骨質疏鬆症患者骨折修復的新方法
  • 開發新型硬骨素抑制劑，以提高骨再生療效並減少脫靶不利事件
  • 單株抗體和雙磷酸鹽聯合治療在治療重度骨質疏鬆症的應用日益廣泛
  • 擴展家庭遠端醫療平台，用於遠端監測骨骼密度和骨折治療效果
  • 用於長期治療骨質疏鬆症的合成代謝藥物的監管核准影響市場進入策略。
  • 研究調節腸道菌叢對提高骨骼密度和降低骨折風險的影響

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

8. 依治療類型分類的骨質疏鬆症和骨折治療市場

  • 雙磷酸鹽
    • 阿崙膦酸鈉
    • Ibandronate sodium
    • 利塞膦酸鈉
    • Zoledronic acid
  • 荷爾蒙補充療法
    • 聯合荷爾蒙療法
    • 雌激素療法
  • 單株抗體
    • Denosumab
      • 普羅利亞
      • XGEVA
    • 羅莫索單抗
  • 副甲狀腺素類似物
    • 阿巴洛帕拉肽
    • 特立帕肽
  • 選擇性雌激素受體調節
    • Bazedoxifene
    • Raloxifene

9. 依給藥途徑分類的骨質疏鬆症和骨折治療市場

  • 注射
    • 靜脈
    • 皮下
  • 口服

第10章 依最終使用者分類的骨質疏鬆症和骨折治療市場

  • 居家醫療
  • 醫院
  • 專科診所

第11章 依骨折類型分類的骨質疏鬆症和骨折治療市場

  • 腰部
  • 脊椎
  • 手腕

12. 各地區骨質疏鬆症及骨折治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 按組別分類的骨質疏鬆症和骨折治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國骨質疏鬆症及骨折治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Amgen Inc.
    • Stryker Corporation
    • Medtronic plc
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Orthofix Medical Inc.
Product Code: MRR-CA17E905EAC5

The Anti-Osteoporosis Therapy & Fracture Healing Market is projected to grow by USD 29.35 billion at a CAGR of 8.78% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 14.97 billion
Estimated Year [2025] USD 16.28 billion
Forecast Year [2032] USD 29.35 billion
CAGR (%) 8.78%

A concise framing of clinical priorities, therapeutic evolution, and delivery model dynamics shaping anti-osteoporosis care and fracture healing pathways

Osteoporosis and fracture healing occupy a central position in aging-population healthcare strategies and in therapeutic innovation agendas worldwide. As demographic shifts continue to expand the population at risk, clinical pathways, payer expectations, and delivery models are evolving concurrently. This introduction frames the clinical imperatives and commercial realities that shape decisions by clinicians, hospital systems, payers, and manufacturers.

Contemporary management of low bone mass and fragility fractures relies on an interplay of pharmacologic agents, device-facilitated interventions, and coordinated care pathways that prioritize secondary prevention. In parallel, longer-term therapy adherence, route-of-administration preferences, and the emergence of novel biologics are reshaping treatment algorithms. Regulatory approvals, safety communications, and real-world evidence are influencing prescriber confidence and formulary placement in distinct ways across regions.

Against this backdrop, stakeholders must balance clinical efficacy with operational feasibility, recognizing that successful fracture prevention and healing programs demand integration across primary care, specialty clinics, hospitals, and homecare services. This introduction sets the stage for a strategic reading of subsequent sections that analyze transformative industry shifts, trade policy impacts, segmentation intelligence, regional dynamics, competitor activity, and pragmatic recommendations for leaders aiming to convert insight into action.

How biologics, patient-centric administration, precision care pathways, and supply resilience are remapping therapeutic strategies and commercial models

The therapeutic and commercial landscape for osteoporosis and fracture healing is undergoing several concurrently accelerating shifts that are transforming clinical practice and competitive positioning. First, the maturation of monoclonal antibody therapeutics and anabolic agents has redirected treatment sequencing conversations toward rapid fracture risk reduction and bone formation strategies, prompting clinicians to reassess long-standing reliance on antiresorptives alone.

Second, patient-centric care models and adherence-aware device innovations are elevating the importance of route of administration and dosing convenience. Injectable regimens that offer infrequent dosing intervals are changing adherence profiles relative to daily or weekly oral therapies, and this dynamic is prompting payers and providers to reconsider care pathways and support services. Third, the intersection of precision medicine and digital health is enabling more granular risk stratification, with imaging biomarkers and integrated fracture liaison services improving case-finding and timely intervention.

Finally, supply chain resilience and biosimilar competition are emerging as strategic variables in commercial planning. Manufacturers are adapting by diversifying portfolios, pursuing lifecycle management for established agents, and accelerating partnerships that integrate clinical services, diagnostics, and patient support. These transformative shifts are collectively increasing the complexity of commercialization while creating differentiated pathways for organizations that align clinical benefit with operational scalability.

Evaluating the operational and strategic consequences of 2025 tariff adjustments on supply chains, procurement, and therapeutic access across osteoporosis care

The introduction of tariff changes and trade policy adjustments in 2025 has introduced novel cost and supply considerations for stakeholders involved in anti-osteoporosis therapies and fracture-healing products. Tariffs on pharmaceutical inputs and finished goods can increase landed costs for certain therapeutic classes, particularly those with complex biologic manufacturing inputs or reliance on specialized components sourced internationally. This, in turn, affects pricing negotiations, procurement strategies, and inventory management decisions across hospital systems and specialty clinics.

Manufacturers and distributors are responding by re-evaluating global manufacturing footprints, increasing nearshoring investments, and accelerating qualification of alternative API and component suppliers to preserve continuity of supply. In parallel, payers and integrated health systems are intensifying scrutiny of cost-effectiveness and may prioritize therapies with stable supply chains and transparent cost structures. These trends create both headwinds and opportunities: while tariffs introduce short-term margin pressure and procurement complexity, they also incentivize investments in resilient manufacturing, vertical integration, and strategic supplier alliances that can reduce exposure to future trade disruptions.

Moreover, regulatory agencies and customs authorities are placing greater emphasis on documentation and traceability, which requires enhanced coordination between quality, regulatory affairs, and commercial teams. For innovators and established product owners alike, proactive supply chain scenario planning and engagement with procurement stakeholders will be essential to mitigate the cumulative operational impact of tariff shifts and to maintain clinician and patient access to critical therapies.

Dissecting therapy classes, administration routes, care settings, and fracture-specific needs to align clinical evidence and commercial tactics for better adoption

A nuanced reading of market segmentation illuminates where clinical needs, commercial opportunity, and operational friction converge, and it is essential to translate those segment-level characteristics into actionable tactics. Based on therapy type, the landscape spans classic antiresorptives such as bisphosphonates, which are further differentiated into agents like alendronate, ibandronate, risedronate, and zoledronic acid, alongside hormone replacement therapies that include combined hormone options and estrogen-focused strategies. Monoclonal antibody treatments are represented by denosumab and romosozumab, with denosumab delivered under branded indications such as Prolia and Xgeva, while parathyroid hormone analogues include abaloparatide and teriparatide. Selective estrogen receptor modulators such as bazedoxifene and raloxifene continue to occupy niche positions in specific patient cohorts. These therapy distinctions drive differential clinical adoption based on efficacy profiles, safety considerations, patient comorbidities, and formulary positioning.

When considering route of administration, injectable and oral pathways must be weighed against patient convenience, adherence implications, and healthcare delivery capacity; injectable options that can be administered intravenously or subcutaneously often require facility-based resources or trained homecare services, whereas oral agents offer outpatient convenience but face adherence challenges. Examining end users, service delivery occurs across homecare environments, hospitals, and specialty clinics, each with unique procurement, administration, and reimbursement dynamics that influence product selection and support requirements. Fracture type segmentation highlights clinical priority areas-hip, spinal, and wrist fractures-where differences in morbidity, acute care needs, and rehabilitation pathways inform therapeutic urgency and secondary prevention strategies. Taken together, these segmentation lenses should inform targeted clinical evidence generation, tailored patient support programs, and channel-specific commercial tactics to optimize uptake and patient outcomes.

Regional regulatory, reimbursement, and delivery contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and adoption pathways

Regional dynamics continue to shape access, reimbursement, and clinical adoption patterns for osteoporosis therapies and fracture management solutions. In the Americas, demand is influenced by integrated healthcare delivery systems, payer-driven formulary processes, and growing emphasis on value-based contracts tied to outcomes such as fracture reduction and reduced hospital readmissions. These pressures encourage manufacturers to demonstrate real-world effectiveness and to partner with health systems on post-launch evidence generation and patient support programs.

In Europe, Middle East & Africa, regulatory harmonization, national procurement frameworks, and variable reimbursement environments create a mosaic of entry strategies. Country-level differences in pricing negotiation mechanisms and health technology assessment approaches require tailored market access planning and local evidence that addresses specific clinical and economic endpoints. The region also presents opportunities for centralized clinical collaborations and regional manufacturing investments that can improve supply security.

Asia-Pacific markets present diverse trajectories ranging from rapidly expanding access to advanced biologics in high-income urban centers to growing primary care capacity in emerging markets. Local regulatory pathways, rising clinical trial activity, and increasing investment in diagnostic infrastructure are shaping faster adoption of innovative agents in some markets, while in others cost and logistics remain significant barriers. Across all regions, cross-border collaboration on best-practice fracture liaison services and telehealth-enabled monitoring is becoming a differentiator in achieving better patient outcomes and broader therapy penetration.

Competitive strategies centered on biologic innovation, lifecycle management, partnerships, and integrated service offerings that shape product trajectories

Company strategies in the osteoporosis and fracture healing domain reveal a spectrum of approaches, from portfolio diversification and biologic innovation to lifecycle management and service integration. Some leading innovators concentrate on advancing monoclonal antibody and anabolic platforms, leveraging differentiated clinical profiles to secure premium formulary positions and specialist uptake. These organizations invest heavily in long-term safety monitoring, head-to-head comparative trials, and large-scale observational studies to sustain clinician confidence and to inform guideline inclusion.

At the same time, companies with established small-molecule portfolios prioritize cost-containment strategies, manufacturing optimization, and patient support services that improve adherence. Partnerships across diagnostic providers, homecare operators, and digital health firms are increasingly common as firms seek to offer bundled solutions that address the full continuum of fracture prevention and healing. Biosimilar entrants and contract manufacturers are influencing pricing dynamics and supply flexibility, which compels originator companies to accelerate innovation and to explore novel commercial models such as outcome-based pricing.

Across the competitive landscape, intellectual property management, regulatory lifecycle planning, and geographic diversification of manufacturing are recurrent themes. Firms that combine robust clinical evidence, resilient supply chains, and integrated service offerings are positioned to maintain competitiveness, while those that fail to adapt to evolving payer requirements or patient expectations risk erosion of uptake in key channels.

Actionable strategic initiatives emphasizing evidence generation, supply resilience, patient-centered delivery, and novel commercial models to secure competitive advantage

Industry leaders should adopt a coordinated set of strategic actions that align clinical differentiation with operational resilience and payer expectations. First, prioritize generation of real-world evidence and comparative effectiveness data that demonstrate both clinical benefit and systems-level value, enabling stronger negotiations with payers and inclusion in guideline-driven care pathways. Second, invest in supply chain diversification and incremental nearshoring to reduce exposure to tariff and trade disruptions, while ensuring that quality and regulatory compliance are preserved through robust supplier qualification processes.

Third, design patient-centric support programs and administration pathways that reconcile the convenience of oral agents with the adherence advantages of infrequent injectable regimens; incorporate telehealth, nursing support, and digital reminders to improve persistence. Fourth, pursue strategic collaborations with diagnostic providers and fracture liaison services to strengthen case-finding and secondary prevention workflows, thereby improving outcomes and reinforcing value-based contracting opportunities. Fifth, consider adaptive commercial models such as risk-sharing agreements and bundled payments for fracture care that align incentives across stakeholders.

Finally, embed regulatory and health technology assessment planning early in product development and life-cycle activities to expedite access and to address payer evidence requirements proactively. By aligning clinical, operational, and commercial priorities, leaders can convert emerging trends into sustainable competitive advantage.

An integrated, expert-validated research approach combining primary clinical and payer interviews with rigorous secondary evidence synthesis and scenario analysis

The research methodology underpinning this analysis integrates multi-source evidence, expert validation, and iterative triangulation to produce actionable insights. Primary research comprised structured interviews and advisory consultations with clinical specialists in endocrinology and orthopedics, hospital pharmacy directors, specialty clinic administrators, and payer and procurement representatives, providing direct perspectives on prescribing behavior, formulary decision-making, and care delivery constraints.

Secondary research included systematic review of regulatory approvals, peer-reviewed clinical literature, guideline statements, product labels, and publicly available safety communications to ensure alignment with the most recent clinical and regulatory developments. Real-world evidence sources such as health services utilization reports, clinical registries, and published outcomes research were examined to contextualize therapeutic performance and post-market experiences.

Data synthesis relied on cross-validation between primary insights and secondary datasets, with thematic coding used to identify recurrent opportunities and risks. Scenario analysis and sensitivity testing were employed to evaluate the operational impact of supply chain and trade policy changes. Throughout the research process, quality assurance protocols ensured source traceability and consistency, and subject-matter experts reviewed draft findings to confirm clinical plausibility and commercial relevance.

Summative insights that link therapeutic innovation, delivery transformation, and operational resilience into a clear pathway for sustained impact in fracture prevention and healing

In conclusion, the anti-osteoporosis therapy and fracture healing landscape is at an inflection point driven by therapeutic innovation, evolving care delivery models, and emerging supply chain and trade policy considerations. The ascent of anabolic and monoclonal antibody therapies is redefining clinical decision-making, while adherence and route-of-administration dynamics continue to influence real-world effectiveness. Meanwhile, tariff-induced supply chain considerations and growing payer emphasis on outcomes are reshaping commercialization tactics and operational planning.

Stakeholders who proactively integrate robust evidence generation, flexible manufacturing and sourcing strategies, and patient-centered delivery models will be better positioned to navigate this complex environment. Cross-sector collaborations that link diagnostics, digital health, and care coordination services have the potential to improve case-finding and reduce downstream fracture burden. Ultimately, the organizations that align scientific differentiation with demonstrable health-system value and resilient operations will capture durable opportunities in both established and emerging markets.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancement of romosozumab therapy under scrutiny for cardiovascular safety in high-risk osteoporosis patients
  • 5.2. Integration of wearable sensors and AI algorithms to monitor bone healing progression in real time
  • 5.3. Emerging use of gene therapy approaches targeting osteoblast activity to accelerate fracture repair in osteoporosis sufferers
  • 5.4. Development of novel sclerostin inhibitors with improved efficacy and reduced off-target adverse events in bone regeneration
  • 5.5. Increasing adoption of combination regimens of monoclonal antibodies and bisphosphonates for severe osteoporosis management
  • 5.6. Expansion of home-based telehealth platforms for remote monitoring of bone density and fracture healing outcomes
  • 5.7. Regulatory approvals of anabolic agents for long-term osteoporosis treatment shaping market access strategies
  • 5.8. Investigating the impact of gut microbiome modulation on bone density improvement and fracture risk reduction

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Osteoporosis Therapy & Fracture Healing Market, by Therapy Type

  • 8.1. Bisphosphonates
    • 8.1.1. Alendronate
    • 8.1.2. Ibandronate
    • 8.1.3. Risedronate
    • 8.1.4. Zoledronic Acid
  • 8.2. Hormone Replacement Therapy
    • 8.2.1. Combined Hormone Therapy
    • 8.2.2. Estrogen Therapy
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Denosumab
      • 8.3.1.1. Prolia
      • 8.3.1.2. Xgeva
    • 8.3.2. Romosozumab
  • 8.4. Parathyroid Hormone Analogues
    • 8.4.1. Abaloparatide
    • 8.4.2. Teriparatide
  • 8.5. Selective Estrogen Receptor Modulators
    • 8.5.1. Bazedoxifene
    • 8.5.2. Raloxifene

9. Anti-Osteoporosis Therapy & Fracture Healing Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Oral

10. Anti-Osteoporosis Therapy & Fracture Healing Market, by End User

  • 10.1. Homecare
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Anti-Osteoporosis Therapy & Fracture Healing Market, by Fracture Type

  • 11.1. Hip
  • 11.2. Spinal
  • 11.3. Wrist

12. Anti-Osteoporosis Therapy & Fracture Healing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Osteoporosis Therapy & Fracture Healing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Osteoporosis Therapy & Fracture Healing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Amgen Inc.
    • 15.3.2. Stryker Corporation
    • 15.3.3. Medtronic plc
    • 15.3.4. Novartis AG
    • 15.3.5. Merck & Co., Inc.
    • 15.3.6. Teva Pharmaceutical Industries Ltd.
    • 15.3.7. Eli Lilly and Company
    • 15.3.8. Orthofix Medical Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ALENDRONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY IBANDRONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RISEDRONATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ZOLEDRONIC ACID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COMBINED HORMONE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ESTROGEN THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PROLIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY XGEVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROMOSOZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ABALOPARATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY TERIPARATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BAZEDOXIFENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY RALOXIFENE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOMECARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SPINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY WRIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY DENOSUMAB, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY PARATHYROID HORMONE ANALOGUES, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY SELECTIVE ESTROGEN RECEPTOR MODULATORS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY FRACTURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY BISPHOSPHONATES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTI-OSTEOPOROSIS THERAPY & FRACTURE HEALING MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2025-2032 (USD